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To appropriately plan for rollout and monitor impact of oral pre-exposure prophylaxis (PrEP) it 
is important to understand PrEP continuation and come to a consensus on how best to measure 
PrEP continuation. This study reviews data on PrEP continuation to document how it is reported, 
and to compare continuation over time and across populations.  
Design 
Systematic review and meta-analysis. 
Methods  
We searched MEDLINE, Embase, and Global Health and reviewed abstracts from HIV 
conferences from 2017-2018 for studies reporting primary data on PrEP continuation. Findings 
were summarized along a PrEP cascade and continuation was presented by population at months 
1, 6, and 12, with random-effects meta-analysis. 
Results 
Of 2,578 articles and 596 abstracts identified, 41 studies were eligible covering 22,034 
individuals. Continuation data were measured and reported inconsistently. Results showed high 
discontinuation at month 1 and persistent discontinuation at later time points in many studies. 
Pooled continuation estimates were 66% at month 1 (n=5,348; 95% CI: 48%-82%), 63% at 
month 6 (n=13,629; 95% CI: 48%-77%), and 71% at month 12 (n=14,933; 95% CI: 60%-81%; 
higher estimate than previous timepoints due to inclusion of different studies). Adequate data 






This review found that discontinuation at 1 was high, suggesting PrEP initiations may be a poor 
measure of effectiveness.  Continuation declined further over time in many studies, indicating 
existing cross-sectional indicators may not be adequate to understand PrEP use patterns. Studies 
do not measure continuation consistently, and consensus is needed. 









The effectiveness of oral pre-exposure prophylaxis (PrEP) is contingent upon continued use 
during periods of risk for HIV, which evidence shows is difficult for many clients.[1–3] Continual 
engagement in care via follow-up visits is important not only for refills, but for ongoing 
continuation support, risk reduction counseling, screening for sexually transmitted infections 
(STIs), and management of side effects. [4–6] The World Health Organization (WHO) and 
national PrEP guidelines recommend that PrEP clients are tested for HIV at one and three 
months after initiation and every three months thereafter. [7,8] Despite increasing adoption of 
PrEP, [9] there have been challenges in achieving continued engagement in follow-up visits. 
As countries approve PrEP for HIV prevention and prepare for widespread provision, monitoring 
of continued follow-up and refill – or continuation - is essential to estimate the potential impact 
of the intervention and eventually measure the success of PrEP programs. Continuation data can 
inform costing of PrEP implementation by providing evidence of the likelihood that PrEP clients 
will return at each follow-up visit, helping to adequately project the cost of PrEP provision over 
time. Continuation data can also provide insight into whether some population groups are more 
or less likely to continue on PrEP and help ensure that strategies to promote PrEP continuation 
are designed to meet the requirements of specific populations. 
Despite the importance of consistent measurement of PrEP continuation, there is little consensus 
on how to do so. Conversations about the appropriate indicators to measure PrEP program 
success are ongoing, and approaches are rapidly evolving. Consensus is building that the word 
“retention” is not appropriate for prevention, because unlike antiretroviral therapy (ART), PrEP 
is not taken for life; at times clients may safely cycle on and off of PrEP, in consultation with 





often used interchangeably. Further complication arises with different dosing for different 
populations. WHO guidance supports intermittent, event-driven, or “on demand” dosing for men 
who have sex with men (MSM) and provision of time-limited PrEP to HIV-negative people in 
serodiscordant relationships. [7] Existing PrEP indicators, including those endorsed by the 
WHO[7] and PEPFAR, [10] do not account for differences in dosing schedules or safe cycling.  
This systematic review and meta-analysis will document reporting of continuation in published 
literature and compare continuation across diverse populations. The analysis will inform the 
ongoing conversation about how to measure PrEP program success, support future modelling 
and costing studies, and highlight how PrEP continuation vary among target populations. 
 
Methods 
Search strategy and selection criteria 
The purpose of this systematic review and meta-analysis was to identify data from clinical trials, 
demonstration projects, and real-world settings on participant continuation on oral PrEP Due to 
the limited evidence base currently available on this topic, the search was intended to cover 
programs run among any of the target groups considered to be at risk of HIV infection and in any 
setting. Only those studies reporting on primary data were deemed eligible, with modelling 
studies and simulations excluded. Studies on programs utilizing methods other than oral PrEP 
delivery (e.g., topical gels, vaginal rings) were also excluded. Where trials or studies included 
two modes of delivery (i.e., one oral PrEP and one other, or one oral PrEP and one placebo), 
only data from the oral PrEP arm were included. Studies reporting on eligibility and enrolment 





A literature search was run on three databases (MEDLINE, Embase, and Global Health) to 
identify articles written in English and published in 2010 or later. Search terms used were (“pre-
exposure prophylaxis” OR “PrEP”) AND (“HIV” OR “HIV/AIDS”) AND (“implementation” 
OR “demonstration” OR “observation” OR “trial” OR “open label extension”). The search was 
completed on November 6, 2018. Titles and abstracts were screened initially, followed by review 
of full text articles deemed potentially eligible for inclusion. In addition to the database searches, 
abstracts from the Conference on Retroviruses and Opportunistic Infections (CROI) in 2017 and 
2018, the 22nd International AIDS Conference (AIDS 2018), and the 2017 International AIDS 
Society (IAS) Conference were also screened on the basis of their titles, and full abstracts were 
reviewed when they were deemed potentially eligible for inclusion. 
Study screening and extraction 
The primary outcome for this review is continuation in PrEP 
services at various time points, which are represented along a 
simplified  PrEP cascade in Figure 1 [11].  Continuation data were 
extracted from the literature and mapped to the timepoints in this 
cascade. It is important to note that studies reporting on 
continuation in PrEP services cover PrEP programs of varying 
structures, with study visits occurring and continuation reported 
at different intervals.  The cascade is not an accurate reflection 
of each study visit in every study included but affords the benefit 
of allowing for comparison between studies. When continuation was reported between time 
points, the continuation value was presented for the closest preceding timepoint. Note that many 





proposed PrEP services cascades also include adherence, or effective use[11–13]; however, this 
important indicator of PrEP program success is beyond the scope of this review.  
For the purpose of this analysis, continuation at each point in the PrEP cascade is defined as the 
number or proportion of enrolled or initiated study participants who returned for a follow-up visit 
at the relevant time point. This definition does not account for true duration of use among clients 
who discontinue as these data are not available– instead, clients who do not return to the study 
visit are considered to have discontinued use at the time of the visit. We also do not account for 
use of PrEP during periods of risk and discontinuation when no longer at risk, which is 
sometimes referred to as prevention-effective use or prevention-effective adherence. [14–16] 
Limiting our interpretation of effective continuation to only continual use over time could 
underestimate the impact of PrEP, ignoring the risk averted by those with other use patterns. 
However, none of the studies in this review tracked prevention-effective use, so we report on 
PrEP continuation only as continual use time.  
Data were extracted and entered into Excel. Four weeks were considered one month for 
continuation reported at weekly intervals. If no specific population group was targeted in the 
study, the population was deemed “All at risk”. When continuation at different points in the 
cascade was reported separately by study population or study site, the continuation data were 
extracted separately for each population or site to allow for comparison. 
Two independent reviewers (JL and KS) completed the full review process to determine studies 
for inclusion. Both reviewers then screened the full text of each study and extracted data, and 







Study quality was assessed using the Joanna Briggs Institute Checklist for Prevalence Studies. [17] 
This tool allows assessment of studies based on study design, implementation, and analysis. No 
papers were excluded, as all were deemed to be of sufficient quality (score of 5 or more).  
All statistical and meta-analyses were completed using Stata 15. [18] We summarized reporting of 
continuation by calculating the percentage of studies reporting on each aspect of the cascade. We 
calculated percent discontinuation between time periods by taking the difference in continuation 
between the time periods. PrEP continuation cascades were developed presenting continuation 
from studies reporting continuation from at least three of the four time points from month 1 to 
month 12. We created forest plots of continuation at month 1, month 6, and month 12, grouped 
by population, using random-effects meta-analysis with Freeman-Tukey double arcsine 
transformation. The analysis was done using Metaprop, a program specifically designed for 
binomial data that calculates confidence intervals within the admissible values of 0-1. [19] We 
estimated pooled continuation and 95% confidence intervals (CIs) overall, and not by population, 
because of high heterogeneity (I2 statistic) within groups.  
Role of the funding source  
This work was funded by the US Agency for International Development and led by the 
OPTIONS Consortium. The funders did not play any role in the study design, data collection and 








The search yielded 2,578 articles and 596 abstracts, of which 249 were retained for full text 
review (As depicted in Appendix S1; see Supplemental Digital Content, 
http://links.lww.com/QAD/B770). Fifty records met the inclusion criteria for this review, covering 
41 individual trials, demonstration projects, or routine implementation/clinical programs.  
Study Characteristics 
Key features of the studies, including type of study, site, and study population are included in 
Appendix 2 (see Supplemental Digital Content, http://links.lww.com/QAD/B770). Although some 
trials published multiple papers, they all contributed to a single record if they reported on the 
same data. On the other hand, a single paper is considered to contribute to multiple studies if it 
reported data along the cascade separately by population or location. The 41 programs covered 
by the studies in this review included 24 open-label or demonstration projects, nine routine 
implementation/clinical programs, and eight randomized controlled trials (RCTs). Studies were 
most commonly conducted in Africa (16, 39%) and North America (12, 29%). Populations most 
commonly reported were MSM and transgender women (TGW) (18, 44%), all people at risk (9, 





Reporting of PrEP cascade components 
Table 1 presents the number of clients screened, eligible, and enrolled/initiated for each study, 
along with the percentage of those enrolled/initiated still retained in care (continuation) at each 
time point of the PrEP services cascade. No studies reported prevention-effective use and none 
discussed a continuation definition that suggested continued need for PrEP was considered in the 
statistics presented. Reported components of the PrEP services cascade varied by study, as 
shown in Figure 2.  
 
 
Figure 2: Components of the PrEP services cascade reported in literature review 
 
Just under half of studies reported the numbers of clients screened and the number of clients 
determined eligible for PrEP. All studies reported number of clients enrolled/initiated (a 
requirement for inclusion) but reported this information in different ways. Some studies reported 





started taking PrEP, and sometimes these numbers differed from those enrolled. [21] We reported 
the number who started taking PrEP as enrolled/initiated when such information was provided. 
 
Continuation was most commonly reported at month 6, followed by months 3 and 12, and then 
month 1. Continuation past one year was rarely reported and was not reported in any of the 
routine implementation studies included in this review. Other time points at which continuation 
was reported were months 4, 9, 15, 16, 18, and 20, [31,35,43] and weeks 6, 10, 14, 18, 22, 26, 30, 
34. [55,58] 
 
Some studies only reported continuation as total or average length of follow-up (in days, months, 
or years). Since it was not possible to fit these data into the PrEP cascade, those studies were 
excluded. Other methods for reporting continuation included using the number who “opted out” 
at certain time points[24] or the percentage retained among those still remaining in the study at the 
previous time point. [48] 
Continuation up to one year  
All studies reported continuation at a minimum of one time point within one year of initiation. 
Continuation at each time point varied greatly across studies, with some studies maintaining 
relatively high continuation over time and others with an immediate drop-off. To compare 
continuation within studies over time we looked at continuation among studies reporting three or 
more of the four timepoints up to month 12 in Figure 3. Average continuation among these 
studies was: 65% (M1), 62% (M3), 51% (M6), and 43% (M12). Percent discontinuation between 
time periods varied by study, with discontinuation ranging from 2% to 18% from months 1-3, 






Figure 3: PrEP continuation cascade among studies reporting on three or more time periods up to 
month 12. 
Continuation after one year 
Few studies reported continuation after month 12. Six of the studies reported continuation at 
month 24, which ranged from 22% to 82%. At 36 months, continuation ranged from 33% to 
77%, as reported by three studies. The only study providing continuation data past 36 months, 
the Bangkok Tenofovir Study (BTS), reported continuation on PrEP among injection drugs users 






Continuation by population 
We examined continuation by population visually over time using forest plots. Data from 3,107 
MSM, 897 women, 597 all at risk, and 747 female sex workers (FSW) were available for the 
meta-analysis of continuation at month 1 (Figure 4a).  











Figure 4c: Forest plot of continuation by subpopulation at 12 months after initiation 
 
Considerable variation was observed across studies and populations. Significant inter-group 
heterogeneity was observed (p<0.001 and high I2 statistic in each group), so pooled estimates by 
population were omitted. Heterogeneity among groups was also significant, suggesting the 





At six months, a total of 5,050 MSM, 4,164 serodiscordant couples (SDC), 2,050 all at risk, 825 
women, 793 IDUs (from one study), and 747 FSW available for the meta-analysis (Figure 4b). 
Again, heterogeneity was high among studies and across population groups.   
 
 
At month 12, data on 5,449 MSM, 4,164 SDC, 3,005 women, 1,204 IDU (from one study), 866 
FSW, and 245 members of the general population (from one study) were available for the meta-
analysis (Figure 4c). Again, inter-studies and inter-group heterogeneity were high.  
Discussion 
This systematic review synthesizes the growing body of literature on PrEP continuation. The 
results show that the metric by which oral PrEP continuation is measured and reported are not 
consistent. Continuation varies widely across studies and target populations, and continues to 
decline over time. 
Collation of data along the PrEP cascade revealed that the time points at which continuation is 
reported vary widely. This is not surprising, given the abundance of proposed PrEP cascades in 
published literature and the lack of consensus on which components are most important to track. 
[11–13] In studies that reported multiple time points, we found that discontinuation often persisted 
over time, with discontinuation as high as 25% and 35% from months 3 to 6 and from months 6 
to 12, respectively. 
These results have implications for existing monitoring and evaluation guidelines, which focus 





M&E guidelines suggest a core indicator of “Continuation on PrEP,” defined as the “Percentage 
of PrEP users who continued on oral PrEP for three consecutive months after having initiated 
PrEP in the last 12 months.” [7] The decision to limit this indicator to three months was justified 
based on early data from demonstration projects suggesting that many users who discontinue oral 
PrEP do so during the first few months. This review contradicts those early results, given it has 
shown that discontinuation in the studies currently under review was common even after month 
3. 
The PEPFAR oral PrEP indicators also do not promote longitudinal monitoring, rather they 
parallel existing treatment indicators, which give a snapshot of changes in the total number in 
care over time, rather than allowing for an understanding of duration of continuation. [10] While 
M&E indicators of client-level continuation may not be feasible, organizations should promote 
evaluation studies to understand this important dimension of PrEP rollout, without which impact 
and cost-effectiveness cannot be assessed. 
Just under a third of studies reported continuation at month 1; among those, discontinuation was 
high, averaging 37·3%. High discontinuation at month 1 indicates a large percentage of PrEP 
clients are not returning for the first follow-up visit and has important implications for PrEP 
effectiveness. While discontinuation at subsequent time points could be due to periods of low 
risk, discontinuation at one month likely indicates other reasons for stopping. These findings 
suggest that when assessing whether a client should initiate PrEP, attention should be paid to not 
only PrEP eligibility, but also the client’s readiness to take PrEP consistently over time. 
Initiations are costly[59], and no prevention impact can be assumed without at least one return 
visit.  This finding suggests that the number of PrEP initiations may not be a very useful 





Recent studies show that side effects, stigma, influence of partners, difficulty accessing services, 
and reduced HIV-risk perception have contributed to discontinuation in some PrEP users[27, 60, 61]. 
Discontinuation due to lack of risk is an important concept for continuation measurement, as 
discussed previously, that we were unable to account for in our analysis due to lack of data. 
More research is needed to determine the reasons for high early and ongoing discontinuation.  
In designing this review, we felt it was important to make the distinction between continuation of 
all clients who initiated and continuation among just those still at risk or indicated for PrEP, 
known as prevention-effective use.16 No studies in this review reported prevention-effective use 
or stopping and restarting of clients on PrEP. Some studies reported planned cycling or dosing 
schedules, such as studies among serodiscordant couples that promoted PrEP as a bridge to ART 
and the Gaza miners study, which offered PrEP during periods of high risk. [53,56,62] Future 
research is needed to examine cycling among PrEP users and how to appropriately monitor 
prevention-effective use. 
This review found that continuation varied by population and across time. Pooled estimates at 12 
months were actually higher than previous timepoints. This is likely due to different studies 
reporting at the different timepoints, and some studies with particularly low continuation 
reporting at only months 1 and 6[27]. Continuation also varied within populations. Some of this 
variation can likely be attributed to differences in study types, intervention models, and 
mechanisms for client support.  
This systematic review has limitations. Studies had various designs, populations and geographic 
locations. Given the paucity of data on combinations of population, study type, and geography, it 
is not currently possible to examine pooled continuation by just one population, study type, and 





continuation across time so that these analyses can be completed and shed further light on this 
important topic. To better understand PrEP continuation, researchers should consider 
longitudinal studies that account for prevention effective adherence (time at-risk) and explore 
probabilities of continuation via survival analysis or other more robust methods. 
 Some studies had to be excluded because the reported continuation data did not align with the 
cascade used in the study design. We could not distinguish in this review participants who were 
lost to follow-up versus those who went off the product and stayed in the study. Finally, this 
study did not assess the influence of potential confounders. Further research is needed to 
examine the predictors of PrEP continuation and discontinuation to more fully understand this 
important component of PrEP program effectiveness and efficiency. 
Despite these limitations, the findings have implications for the evolving discussion on how to 
monitor PrEP programs and provide valuable information for decision makers. Our analysis of 
continuation suggests that PrEP initiations may not be a good measure of effectiveness and that 
longitudinal monitoring of continuation may be important for understanding long-term use 
patterns. Research should examine methods of ensuring PrEP-readiness prior to initiation and 
reasons for early and later discontinuation. Guidance is needed on how best to measure 
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Table 1: Percentage of participants/clients who continued on PrEP over time 





Percent who continued PrEP (%) 
M1 M3 M6 M12 M24 M36 M48 M60 
Swaziland[20] All at risk 438 333 108 63        
Providence, RI[21] All at risk  80 61  90 70      
Jackson, MS[21] All at risk  61 52 82 73 
St. Louis, MO[21] All at risk  30 26 100 80 
Los Angeles, CA[22] All at risk   1,764 67 54 
One-Step PrEP[23] All at risk 251  245 75 
Pluspills[24] All at risk 244  147 82 58 
Swaziland demo[1] All at risk   217 59 
SEARCH (sub-analysis) [26] All at risk 701 272 16 
Kenya demo FSW[27] FSW   528 40 27 14      
TAPS demo[28,29] FSW 241 224 219 53 43 30 22     
India demo[30] FSW 707 652 647    95     
BTS OLE[31] IDU 1,348 1,315 793  72 59      
BTS[32,33] IDU   1204 88 81 77 71 63 
Atlanta, GA[34] MSM  184 63   39      
Paris clinic[35] MSM  1,069 1049  71 46 16     
San Francisco PrEP 
clinic[36] MSM 344  268    53     
ATN 113[37] MSM 2,864 260 78    60     
PRELUDE[38] MSM   321    81 81    
Kenya demo MSM[27] MSM   438 33 22 15      
Project PrEPare[39] MSM 753 241 68   91      
Project PrEPare 2[39] MSM 2186 400 200    71 71    
PROUD[40,41] MSM  544 541    92 82 76   
Life–Steps[42] MSM 58  50  82 78      
Intermittent PrEP in 
Africa[43] MSM, FSW 107  48  91       










Percent who continued PrEP (%) 
M1 M3 M6 M12 M24 M36 M48 M60 
AMPrEP[45] MSM, TGW   376 89 
ATN 082 OLE[46] MSM, TGW 2,846 1,603 1,225 87 84 77 66 
Be-PrEP-ared[47] MSM, TGW 219 200 97 
IPERGAY OLE[48] MSM, TGW  369 361 98 95 93 86     
Brasil demo[49,50] MSM, TGW 1,270 753 450    83     
US PrEP demo[51] MSM, TGW 1,069  557  88  78     
IPERGAY[52] MSM, TGW 445 414 199  78 60 42 22 
Partners demo project[53] SDC 1,694  985  95 86 51     
Partners PrEP Study[53,55] SDC 7,856 4758 3,179   98 86 47 33   
Mozambique[56] Women 97 74 72 91 
MP3 youth[57] Women 40  28 78 60 42 17     
Kenya demo women[27] Women   619 26 17 10   
FEM–PrEP[1] Women   1,062    80  
HPTN 067/ADAPT[58] Women 294  178 99 95 92      
VOICE[2] Women  2010 1,915    94     
*FSW = Female sex workers, IDU = Injection drug users, MSM = Men who have sex with men, TGW = Transgender women, SDC = 
Serodiscordant couple 
 
 
